Multiple myeloma treatment

Abstract

The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

What is claimed is: 
     
         1 . A method of treating multiple myeloma (MM) in an individual, the method comprising:
 determining or having determined, from a biological sample obtained from the individual’s body, that a level of expression of one or more gene selected from a group consisting of: CCNB1 and CDC2 is indicative of overexpression; and   administering to the individual an effective amount of trichostatin A (TSA),   wherein the effective amount is between about 0.01 mg/kg/day and about 100 mg/kg/day and effective to decrease expression of the one or more gene.   
     
     
         2 . The method of  claim 1 , wherein the effective amount is an amount sufficient to decrease expression of each of CCNB1 and CDC2. 
     
     
         3 . The method of  claim 1 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day. 
     
     
         4 . The method of  claim 1 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day. 
     
     
         5 . The improvement of  claim 1 , wherein the TSA is administered orally. 
     
     
         6 . The improvement of  claim 1 , wherein the TSA is administered intravenously. 
     
     
         7 . In a method of treating a patient diagnosed with multiple myeloma (MM) with trichostatin A (TSA), the improvement comprising:
 selecting for treatment with between about 0.01 mg/kg/day and about 100 mg/kg/day a patient determined to overexpress at least one gene selected from a group consisting of: CCNB1 and CDC2.   
     
     
         8 . The improvement of  claim 7 , wherein the effective amount is effective to decrease expression of both of CCNB1 and CDC2. 
     
     
         9 . The improvement of  claim 7 , wherein the amount is between 0.1 mg/kg/day and 10 mg/kg/day. 
     
     
         10 . The improvement of  claim 7 , wherein the amount is between 0.5 mg/kg/day and 5 mg/kg/day. 
     
     
         11 . The improvement of  claim 7 , wherein the TSA is administered orally. 
     
     
         12 . The improvement of  claim 7 , wherein the TSA is administered intravenously.